Loading
A phase 3 trial of Enfortumab vedotin, Cisplatin, Mitomycin C, Gemcitabine and Pembrolizumab in bladder & urothelial cancer, run by Astellas Pharma Global Development, Inc., now recruiting.
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) is a phase 3 interventional study registered as NCT07566156 by Astellas Pharma Global Development, Inc., with 390 participants planned, started 2026-05-11 and due to reach its primary completion in 2030-03-31. Interventions recorded: Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy, Cisplatin, Fluorouracil and Mitomycin C.
Shares Enfortumab vedotin, Astellas, Muscle-invasive and advanced bladder cancer, Pfizer (incl. Seagen) and the tag pipeline.
Shares Mitomycin C, Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares Enfortumab vedotin, Astellas, Muscle-invasive and advanced bladder cancer, Pfizer (incl. Seagen) and the tag pipeline.
Shares Enfortumab vedotin, Astellas, Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.